Insulin

Dexcom Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People

Retrieved on: 
Tuesday, February 6, 2024

The system is available today in Spain, Belgium, and Poland and launches next week in the Netherlands.

Key Points: 
  • The system is available today in Spain, Belgium, and Poland and launches next week in the Netherlands.
  • In some countries Dexcom ONE+ replaces the previous generation Dexcom ONE sensor.
  • Dexcom also incorporated feedback from both end users and healthcare professionals when building Dexcom ONE+, ensuring an easy-to-use, highly effective, CGM experience for people treating their Type 1 or Type 2 diabetes with insulin.
  • Dexcom ONE+ is available today in Spain, Belgium and Poland, and will be available in the Netherlands next week.

The uncertain fate of patients needing life-saving dialysis treatment in Gaza

Retrieved on: 
Tuesday, February 6, 2024

The WHO says that, as of Jan. 5, there have been more than 600 attacks on health-care facilities, with 26 out of 36 hospitals in Gaza severely damaged and 79 ambulances targeted.

Key Points: 
  • The WHO says that, as of Jan. 5, there have been more than 600 attacks on health-care facilities, with 26 out of 36 hospitals in Gaza severely damaged and 79 ambulances targeted.
  • Over 300 health-care workers have been killed and over 200 have been detained by Israeli forces.
  • This leaves patients with chronic life-threatening diseases, such as cancer, heart failure and end-stage kidney disease, with severely limited access to the ongoing medical care they need to survive.

Patients unable to access care for chronic conditions

  • As nephrologists and internal medicine physicians, we are gravely concerned about patients in Gaza with chronic diseases who are unable to access care.
  • There are more than 1,100 dialysis patients, including 38 children, in Gaza.
  • Without adequate dialysis, fluid and toxins accumulate and patients typically die within days to weeks from respiratory failure or cardiac arrest.
  • But in a health-care system under assault, patients are fortunate to receive any dialysis at all.

Patients needing life-saving treatment

  • She then attempted to access dialysis at Al-Awda and Kamal Adwan hospitals, but both facilities had insufficient capacity to treat him.
  • This is a tremendous challenge for dialysis patients who are faced with the uncertainty of when, where or if they will access their life-saving therapy.
  • Anssam, age 12, was displaced from Jabaliya in northern Gaza to seek treatment in Deir El Balah in central Gaza.
  • She had gone 15 days without dialysis and had to leave with her mother to receive life-saving medical treatment.

Loss of medical personnel

  • Beyond the destruction of health-care facilities and a critical shortage of supplies, the loss of medical personnel may have the most devastating and longest-lasting impact on the health-care system in Gaza.
  • He had hopes to expand dialysis care in Gaza and build a nephrology educational training program.
  • His loss resonated far beyond his family, patients and colleagues in Gaza.
  • We join the UN, the WHO, MSF and the British Medical Association, along with millions around the world, who call for an immediate ceasefire and unimpeded humanitarian aid.


The authors do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

How much weight do you actually need to lose? It might be a lot less than you think

Retrieved on: 
Monday, February 5, 2024

But type “setting a weight loss goal” into any online search engine and you’ll likely be left with more questions than answers.

Key Points: 
  • But type “setting a weight loss goal” into any online search engine and you’ll likely be left with more questions than answers.
  • They’ll typically use a body mass index (BMI) calculator to confirm a “healthy” weight and provide a goal weight based on this range.
  • Most sales pitches will suggest you need to lose substantial amounts of weight to be healthy – making weight loss seem an impossible task.

Using BMI to define our target weight is flawed

  • So it’s no surprise we use measurements and equations to score our weight.
  • BMI classifies bodies as underweight, normal (healthy) weight, overweight or obese and can be a useful tool for weight and health screening.


fails to consider two critical factors related to body weight and health – body fat percentage and distribution
does not account for significant differences in body composition based on gender, ethnicity and age.

How does losing weight benefit our health?

  • Losing just 5–10% of our body weight – between 6 and 12kg for someone weighing 120kg – can significantly improve our health in four key ways.
  • But research shows improvements in total cholesterol, LDL cholesterol and triglyceride levels are evident with just 5% weight loss.
  • Excess weight is linked to high blood pressure in several ways, including changing how our sympathetic nervous system, blood vessels and hormones regulate our blood pressure.
  • A meta-analysis of 25 trials on the influence of weight reduction on blood pressure also found every kilo of weight loss improved blood pressure by one point.
  • Research shows just 7% weight loss reduces risk of developing type 2 diabetes by 58%.
  • In one study each kilogram of weight loss resulted in a fourfold decrease in the load exerted on the knee in each step taken during daily activities.

Focus on long-term habits

  • An analysis of 29 long-term weight-loss studies found participants regained more than half of the weight lost within two years.
  • When we lose weight, we take our body out of its comfort zone and trigger its survival response.
  • Read more:
    What's the 'weight set point', and why does it make it so hard to keep weight off?


losing weight in small manageable chunks you can sustain, specifically periods of weight loss, followed by periods of weight maintenance, and so on, until you achieve your goal weight
making gradual changes to your lifestyle to ensure you form habits that last a lifetime.
Setting a goal to reach a healthy weight can feel daunting. But it doesn’t have to be a pre-defined weight according to a “healthy” BMI range. Losing 5–10% of our body weight will result in immediate health benefits. At the Boden Group, Charles Perkins Centre, we are studying the science of obesity and running clinical trials for weight loss. You can register here to express your interest.
Dr Nick Fuller works for the University of Sydney and has received external funding for projects relating to the treatment of overweight and obesity. He is the author and founder of the Interval Weight Loss program.

Ibogaine By David Dardashti Shares Insight On New Study By Stanford University

Retrieved on: 
Thursday, February 1, 2024

The study, which involved soldiers who had experienced both physical and psychological trauma, offers insight towards the potential therapeutic benefits of ibogaine.

Key Points: 
  • The study, which involved soldiers who had experienced both physical and psychological trauma, offers insight towards the potential therapeutic benefits of ibogaine.
  • The University of California has asserted that ibogaine has the ability to increase serotonin levels, which may contribute to the recovery of damaged brain cells.
  • Medicalnewstoday, a leading source of medical news and information, has also reported on the potential of ibogaine in promoting cell recovery.
  • Ibogaine By David Dardashti is proud to be at the forefront of this research and looks forward to further advancements in the field.

MDB Capital Holdings Issues Annual Letter to Shareholders

Retrieved on: 
Wednesday, January 31, 2024

Addison, TX, Jan. 31, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today released its annual letter to shareholders from its CEO and Co-Founder, Christopher Marlett.

Key Points: 
  • Addison, TX, Jan. 31, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today released its annual letter to shareholders from its CEO and Co-Founder, Christopher Marlett.
  • To the Shareholders of MDB Capital Holdings, LLC:
    Welcome to our first annual letter, which I plan to send every January to reflect on the past year and how what we learned will shape our plans for the following year.
  • Undervalued Public Companies: We identify and partner with more mature public companies with undervalued technologies that possess significant leadership potential.
  • We then combine that with our community of experienced investors that commit not only their monetary capital, but their intellectual capital to help each company succeed.

Cardiometabolic Health Congress (CMHC) To Host DIETARY STRATEGIES FOR REVERSING TYPE 2 DIABETES: Advances, Perspectives, and Expert Discussions Live Webinar in Honor of the Late Dr. Sarah Hallberg

Retrieved on: 
Tuesday, January 30, 2024

Boca Raton, FL, Jan. 30, 2024 (GLOBE NEWSWIRE) -- On Saturday, February 24, at 9:00 AM EST , the Cardiometabolic Health Congress (CMHC)  will host a 4.5-hour live, complimentary legacy course in honor of the late Dr. Sarah Hallberg .

Key Points: 
  • Boca Raton, FL, Jan. 30, 2024 (GLOBE NEWSWIRE) -- On Saturday, February 24, at 9:00 AM EST , the Cardiometabolic Health Congress (CMHC)  will host a 4.5-hour live, complimentary legacy course in honor of the late Dr. Sarah Hallberg .
  • Dr. Hallberg passed in March of 2022 after a 5-year battle with stage IV lung cancer.
  • Our high-carb and low-fat diets coupled with processed sugars have put insulin on a roller coaster of sorts.
  • Cardiometabolic Health Congress (CMHC) is a single point of access for breakthrough research, comprehensive education, and practical clinical strategies surrounding cardiometabolic health.

Longer-Term Nut Consumption Improves Brain Insulin Sensitivity, New Study Finds

Retrieved on: 
Thursday, February 1, 2024

BARCELONA, Spain , Feb. 1, 2024 /PRNewswire/ -- Results from a recent INC-funded intervention study were published in the American Journal of Clinical Nutrition [1]. The study showed that, for older adults with overweight or obesity, longer-term consumption of mixed nuts significantly improved brain insulin sensitivity. This may be important for the prevention of age-related metabolic and cognitive diseases.

Key Points: 
  • The study showed that, for older adults with overweight or obesity, longer-term consumption of mixed nuts significantly improved brain insulin sensitivity.
  • Cerebral blood flow (CBF) was quantified using magnetic resonance imaging (MRI), while brain insulin sensitivity was assessed by measuring regional CBF responses to intranasal insulin.
  • The study found that nut consumption significantly improved insulin action in (occipital and frontal) brain regions involved in the modulation of metabolic and cognitive processes.
  • However, intrahepatic lipid content, serum LDL ("bad") cholesterol and systolic blood pressure were lower following nut consumption compared to the control period.

EQS-News: SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory

Retrieved on: 
Tuesday, January 30, 2024

“With our 2023 results, we have delivered on all our targets and have proven that SCHOTT Pharma is a highly profitable business.

Key Points: 
  • “With our 2023 results, we have delivered on all our targets and have proven that SCHOTT Pharma is a highly profitable business.
  • We will continue to benefit from key pharma trends and the overall market growth for injectable drugs”, said Almuth Steinkühler, CFO of SCHOTT Pharma.
  • In 2023, SCHOTT Pharma continued to deliver on its strategy and achieved several milestones along the pillars expansion and innovation.
  • On the innovation side, SCHOTT Pharma successfully introduced two leading innovations to the market that serve the pharma megatrends Glucagon-like peptide-1 (GLP-1) and mRNA.

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

Retrieved on: 
Monday, January 22, 2024

In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.

Key Points: 
  • In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.
  • Tolimidone is an activator of lyn kinase which has been shown to play a significant role in cell proliferation, differentiation, apoptosis, migration and metabolism.
  • We expect to report data from the in vivo LMD efficacy model by the end of the first quarter of 2024.
  • Certain statements in this shareholder letter may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States.

Leading Journal Unveils Groundbreaking Efficacy of Novel Treatment for Obesity, Diabetes, and Liver Disease

Retrieved on: 
Thursday, January 18, 2024

The study, authored by an international team of prominent researchers, appeared in Gut, which is the leading international journal in the field of gastroenterology.

Key Points: 
  • The study, authored by an international team of prominent researchers, appeared in Gut, which is the leading international journal in the field of gastroenterology.
  • Substantial improvements in how the body handles insulin and reduces glucose in the liver compared to controls.
  • Markedly improved response to insulin, enhanced overall body’s use of glucose, and beneficial changes in metabolic health-related gut bacteria.
  • Should the upcoming trials, as anticipated, confirm the safety and efficacy demonstrated in animal studies, this device is poised to transform the treatment of severe and morbid obesity in the years ahead.